SecBot SecBot
PRESS-RELEASE ·Filed May 26, 2026

APGE

Apogee Therapeutics
NEUTRAL
Impact 6/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

The upcoming Phase 2 data readout is a high-impact binary event. Traders should monitor the May 27 results and conference call for efficacy and safety signals. Positive data could drive substantial upside given the large I&I market opportunity; negative data could lead to significant downside.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$77.75
T+0 close · May 26, 2026 · via day close
Latest settled
+73.31%
T+60 · $134.75
Vs SPY
+71.43%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 27 $77.75entry
  2. T+1 · 6mo ago +0.09%α −0.46% · $77.82
  3. T+5 · 6mo ago +1.23%α +0.03% · $78.71
  4. T+20 · 5mo ago +70.65%α +72.55% · $132.68
  5. T+60 · 3mo ago +73.31%α +71.43% · $134.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics announced it will release Part B 16-week data from the Phase 2 APEX trial of zumilokibart on May 27, 2026, followed by a conference call. This is a binary catalyst event for the clinical-stage biotech, as zumilokibart is its most advanced program targeting atopic dermatitis, asthma, and eosinophilic esophagitis.

Key Facts

  • Part B 16-week data from Phase 2 APEX trial of zumilokibart to be reported on May 27, 2026.
  • Conference call and webcast scheduled for 8:00 a.m. ET on May 27, 2026.
  • Zumilokibart is Apogee's most advanced program, targeting atopic dermatitis, asthma, and EoE.
  • Apogee is a clinical-stage biotechnology company with no approved products or reported revenue.

Financial Impact

No financial data provided; outcome of data readout could significantly impact valuation given early-stage nature.

market_capcash_runway

Risk Factors

  • Negative or mixed Phase 2 data could severely impact stock price, as zumilokibart is the lead asset.
  • Clinical-stage biotech with no revenue; cash runway and future financing needs depend on trial outcomes.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3301436

Track record

31 reports on APGE

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (11h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026